Organoid study sheds light on how colorectal cancer cells may avoid immunotherapy

Written by Jade Parker, Senior Editor

Photo credit: Hubrecht Organoid Technology (HUB) Researchers from The Institute of Cancer Research and The Royal Marsden NHS Foundation (both London, UK) have used organoids to reveal how cancers are able to hide from cibisatamab, a promising immunotherapy. Cibisatamab has shown promising results in early trials, but the researchers wanted to find out why some colorectal cancers (CRCs) are resistant to treatment, and to identify ways of making it work for more patients. Utilizing patient-derived CRC organoids, the team observed that CRC cells are able to evade the expected effects of cibisatamab by switching from high to low levels of a...

To view this content, please register now for access

It's completely free